Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injury
Clinical Gastroenterology and Hepatology · 2026-08 · 24 (8) · 2204-2214
DOI: 10.1016/j.cgh.2025.11.006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-08. Verfasst von Frank Erhard Uschner und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine B, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Terlipressin, Hepatorenal Syndrome, Renal Insufficiency, Chronic, Lypressin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Essen, Medizinischen Hochschule Hannover, Martin-Luther-Universität Halle-Wittenberg.
Abstract (Originalsprache)
BACKGROUND & AIMS: Efficacy of treatment with terlipressin and its impact on outcome in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI) and chronic kidney disease (CKD) is unknown. This multicenter, retrospective, observational study aimed to investigate treatment response of terlipressin (+ albumin) in patients with HRS-AKI and CKD compared with patients without CKD. METHODS: A total of 395 patients who received albumin/terlipressin were retrospectively analyzed and stratified according to presence of CKD at baseline. The primary endpoint was a complete response to terlipressin treatment. Secondary endpoints included adverse events, need for renal replacement therapy and 12-month liver transplantation-free survival. RESULTS: A total of 37.6% of patients with CKD and 45.6% of patients without CKD (P = .201) had complete treatment response. CKD had no influence on treatment response to terlipressin (subdistribution hazard ratio [sHR], 0.80 [95% confidence interval (CI), 0.58-1.10]; P = .171). Only delta serum creatinine was significantly associated with complete treatment response to terlipressin (sHR, 0.59 [95% CI, 0.47-0.74]; P < .001) without more complications overall (19.8% vs 15.3%; P = .350). However, patients with CKD had more pulmonary edema (5.9% vs 1.7%; P = .036). Mortality (30 days: 32.7% vs 28.6%; P = .450; 1 year: 43.6% vs 41.5%; P = .727) as well as need for renal replacement therapy during follow-up (26.7% vs 22.8%; P = .498) was similar between groups. After adjusting for Model for End-Stage Liver Disease score and treatment response, CKD did not impact survival in patients with HRS-AKI (sHR, 1.08 [95% CI, 0.63-1.72]; P = .759) considering liver transplantation as competing event. CONCLUSIONS: CKD does not adversely affect treatment response to terlipressin or survival in patients with HRS-AKI. CLINICALTRIALS: gov, Number: NCT06161766.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine B, University Hospital Münster, Münster, Germany.
- Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
- Department of Gastroenterology, Hepatology and Transplant Medicine, University of Duisburg-Essen, Essen, Germany.
- Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Medical Clinic 1, University Hospital, Goethe-University Frankfurt, Frankfurt am Main, Germany.
- Department of Internal Medicine IV, Jena University Hospital, Jena, Germany.
Förderung
- Universitätsklinikum Essen
- Medizinischen Hochschule Hannover
- Martin-Luther-Universität Halle-Wittenberg
Zitieren
APA
Uschner, F. E., Schleicher, E. M., Passenberg, M., Pohl, J., Praktiknjo, M., Volk, A. T., Karbannek, H., Chang, J., Große, K., Rohrer, C., Labenz, C., Maasoumy, B., Jamme, P., von Widdern, J. C., Queck, A., Trebicka, J., Engelmann, C., Rashidi-Alavijeh, J., Bettinger, D., …, & German Cirrhosis Study Group (2026). Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injury. Clinical Gastroenterology and Hepatology, 24(8), 2204-2214. https://doi.org/10.1016/j.cgh.2025.11.006
Vancouver
Uschner FE, Schleicher EM, Passenberg M, Pohl J, Praktiknjo M, Volk AT, et al. Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injury. Clinical Gastroenterology and Hepatology. 2026;24(8):2204-2214. doi:10.1016/j.cgh.2025.11.006
BibTeX
@article{Uschner2026,
author = {Uschner, Frank Erhard and Schleicher, Eva Maria and Passenberg, Moritz and Pohl, Julian and Praktiknjo, Michael and Volk, Anna Teresa and Karbannek, Henrik and Chang, Johannes and Große, Karsten and Rohrer, Charlotte and Labenz, Christian and Maasoumy, Benjamin and Jamme, Paul and von Widdern, Julian Cardinal and Queck, Alexander and Trebicka, Jonel and Engelmann, Cornelius and Rashidi-Alavijeh, Jassin and Bettinger, Dominik and Ripoll, Cristina and German Cirrhosis Study Group, German Cirrhosis Study Group},
title = {Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injury},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {8},
pages = {2204--2214},
doi = {10.1016/j.cgh.2025.11.006}
}
EUVIMED